GE builds Japanese distribution with NEC deal
GE Medical Systems has signed an agreement with NEC Medical Systems of Tokyo to acquire NEC’s Japanese distribution organization. The deal calls for a joint marketing and distribution network to be established for the firms’ products and
GE Medical Systems has signed an agreement with NEC Medical Systems of Tokyo to acquire NECs Japanese distribution organization. The deal calls for a joint marketing and distribution network to be established for the firms products and services, with GE holding a majority stake in the network. With the agreement, GE adds to its $1 billion operation in Japan, according to executives at GE Medical Systems Asia. GEs Asia-Pacific division manages 10 joint ventures, and has 150 offices and more than 3500 employees.
Under the terms of the deal, NECs Japanese sales offices and its 350 salespeople will be transferred to the joint operation. The network will furnish Asian healthcare facilities with monitoring systems for adult, fetal, and neonatal patients, ECG units, and clinical information systems from GE Marquette Medical Systems. Patient monitors, cardiovascular products, and cerebral nerve diagnostic equipment will come from NEC. GE Marquette products will also continue to be distributed in Japan through existing channels, the company said.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
